Huntington's disease is the most frequent autosomal dominant neurodegenerative disorder;
however, no disease-modifying interventions are available for patients with this disease. The …

Huntington's disease (HD) is a fully penetrant neurodegenerative disease caused by a
dominantly inherited CAG trinucleotide repeat expansion in the huntingtin gene on …

Huntington's disease (HD) is a devastating monogenic neurodegenerative disease
characterized by early, selective pathology in the basal ganglia despite the ubiquitous …

There is strong evidence for brain-related pathologies in COVID-19, some of which could be
a consequence of viral neurotropism, or of neuroinflammation following viral infection. Most …

No disease-slowing treatment exists for Huntington's disease, but its monogenic inheritance
makes it an appealing candidate for the development of therapies targeting processes close …

Background TRACK-HD is a multinational prospective observational study of Huntington's
disease (HD) that examines clinical and biological findings of disease progression in …

Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin
gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis …

Background Disease-modifying treatments are in development for Huntington's disease;
crucial to their success is to identify a timepoint in a patient's life when there is a measurable …

Huntington disease is devastating to patients and their families—with autosomal dominant
inheritance, onset typically in the prime of adult life, progressive course, and a combination …

Biomarkers in whichever modality are tremendously important in diagnosing of disease,
tracking disease progression and clinical trials. This applies in particular for disorders with a …